Select Publications
Book Chapters
2023, '17 Epigenetics', in Atopic Dermatitis : Inside Out Or Outside in, Elsevier, pp. 168 - 178, http://dx.doi.org/10.1016/b978-0-323-84744-5.00017-6
,2023, 'Management of Immunosuppressed Dermatology Patients During COVID-19', in Updates in Clinical Dermatology, Springer Nature Switzerland, pp. 109 - 120, http://dx.doi.org/10.1007/978-3-031-45586-5_11
,2022, 'Epigenetics', in Atopic Dermatitis: Inside Out or Outside In, pp. 168 - 178, http://dx.doi.org/10.1016/B978-0-323-84744-5.00017-6
,2022, 'Follicular Occlusion and Inflammation', in A Comprehensive Guide to Hidradenitis Suppurativa, pp. 89 - 99, http://dx.doi.org/10.1016/B978-0-323-77724-7.00010-3
,2021, 'The skin and diabetes', in Skin and the Heart, pp. 283 - 298, http://dx.doi.org/10.1007/978-3-030-54779-0_18
,2021, 'The skin and diabetes', in Skin and the Heart, pp. C1, http://dx.doi.org/10.1007/978-3-030-54779-0_29
,2021, 'Correction to: The Skin and Diabetes', in Skin and the Heart, Springer International Publishing, pp. C1 - C1, http://dx.doi.org/10.1007/978-3-030-54779-0_29
,2021, 'Research Pipeline I: Oral Therapeutics for Psoriasis', in Advances in Psoriasis, Springer International Publishing, pp. 291 - 302, http://dx.doi.org/10.1007/978-3-030-54859-9_23
,2020, 'Hidradenitis Suppurativa (HS) and other disorders of ‘follicular occlusion’', in Stiehm's Immune Deficiencies: Inborn Errors of Immunity, pp. 773 - 786, http://dx.doi.org/10.1016/B978-0-12-816768-7.00033-8
,2015, 'Autoimmune Blistering Diseases and Corticosteroid Use: A Review of the Evidence', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 459 - 468, http://dx.doi.org/10.1007/978-3-662-45698-9_46
,2015, 'Cyclophosphamide in Autoimmune Blistering Diseases: Safety, Efficacy and Evidence Base', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 507 - 513, http://dx.doi.org/10.1007/978-3-662-45698-9_51
,2015, 'Living with Epidermolysis Bullosa: Reviewing the Impact on Individuals' Quality of Life', in Blistering Diseases: Clinical Features, Pathogenesis, Treatment, Springer Link, pp. 711 - 717, http://dx.doi.org/10.1007/978-3-662-45698-9_74
,Journal articles
2024, 'The Clinical and Molecular Response of Pyoderma Gangrenosum to Interleukin 23 Blockade: Result from a proof-of-concept open-label clinical trial.', J Invest Dermatol, http://dx.doi.org/10.1016/j.jid.2024.10.602
,2024, 'Response to adalimumab in Caucasian and Asian patients with hidradenitis suppurativa: A retrospective cohort study of an Australian cohort stratified by patient-reported ethnicity', Australasian Journal of Dermatology, 65, pp. 560 - 566, http://dx.doi.org/10.1111/ajd.14343
,2024, 'Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized double-blind placebo-controlled clinical trial', British Journal of Dermatology, 191, pp. 508 - 518, http://dx.doi.org/10.1093/bjd/ljae144
,2024, 'Drug survival of biologics in hidradenitis suppurativa: A systematic review and meta-analysis', Journal of the American Academy of Dermatology, 91, pp. 170 - 172, http://dx.doi.org/10.1016/j.jaad.2024.03.028
,2024, 'Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients with Epilepsy', JAMA Dermatology, 160, pp. 631 - 640, http://dx.doi.org/10.1001/jamadermatol.2024.1037
,2024, 'Tissue comparability and bias in hidradenitis suppurativa transcriptomic studies', Proceedings of the National Academy of Sciences of the United States of America, 121, http://dx.doi.org/10.1073/pnas.2404503121
,2024, 'Infectious Disease Screening prior to Systemic Immunomodulatory Therapy in Hidradenitis Suppurativa: Consensus Guidelines from the Asia-Pacific Hidradenitis Suppurativa Foundation', Dermatology, 240, pp. 494 - 506, http://dx.doi.org/10.1159/000534575
,2024, 'Gram-negative anaerobes elicit a robust keratinocytes immune response with potential insights into HS pathogenesis', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.15087
,2024, 'More data are needed to confirm the utility of screening for atypical fibroxanthoma and pleomorphic dermal sarcoma recurrence', Journal of the American Academy of Dermatology, 90, pp. e171 - e173, http://dx.doi.org/10.1016/j.jaad.2023.11.064
,2024, 'Understanding multi-kinase inhibitor-associated cutaneous ulcers may provide molecular insights into the aetiology of pyoderma gangrenosum: A comment on Jeon et al.', Australasian Journal of Dermatology, 65, pp. e81 - e84, http://dx.doi.org/10.1111/ajd.14221
,2024, 'Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial', Journal of Investigative Dermatology, 144, pp. 786 - 793.e1, http://dx.doi.org/10.1016/j.jid.2023.10.005
,2024, 'Comment on Kridin et al.—Considering both relative and absolute risk differences in infection risk between biologics classes in patients with psoriasis', Journal of the European Academy of Dermatology and Venereology, 38, pp. e351 - e353, http://dx.doi.org/10.1111/jdv.19615
,2024, 'Global consensus process to establish a core dataset for hidradenitis suppurativa registries', British Journal of Dermatology, 190, pp. 510 - 518, http://dx.doi.org/10.1093/bjd/ljad454
,2024, 'The serum proteome of pyoderma gangrenosum is more expansive than that of hidradenitis suppurativa', Journal of the European Academy of Dermatology and Venereology, 38, pp. e348 - e350, http://dx.doi.org/10.1111/jdv.19611
,2024, 'Hidradenitis suppurativa: New insights into disease mechanisms and an evolving treatment landscape', British Journal of Dermatology, 190, pp. 149 - 162, http://dx.doi.org/10.1093/bjd/ljad345
,2024, 'Rapid Attenuation of B-Cell and IFN-γ–Associated Chemokines in Clinical Responders to Jak Inhibition with Upadacitinib in Hidradenitis Suppurativa', Journal of Investigative Dermatology, 144, pp. 416 - 419.e5, http://dx.doi.org/10.1016/j.jid.2023.07.023
,2024, 'A systematic review of case–control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14329
,2024, 'Clinical reports: the overarching home for case series and case reports in the BJD', British Journal of Dermatology, 190, pp. 1 - 2, http://dx.doi.org/10.1093/bjd/ljad301
,2024, 'Discrepancies in hidradenitis suppurativa lesion characterization by providers and patients', Journal of the European Academy of Dermatology and Venereology, http://dx.doi.org/10.1111/jdv.19999
,2024, 'Infectious complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis', International Journal of Dermatology, http://dx.doi.org/10.1111/ijd.17527
,2024, 'Laser capture microdissection provides a novel molecular profile of human primary cutaneous melanoma', Pigment Cell and Melanoma Research, 37, pp. 81 - 89, http://dx.doi.org/10.1111/pcmr.13121
,2024, 'Mast cells are upregulated in hidradenitis suppurativa tissue, associated with epithelialized tunnels and normalized by spleen tyrosine kinase antagonism', Experimental Dermatology, 33, http://dx.doi.org/10.1111/exd.14894
,2024, 'Predictors of wound healing after surgical deroofing in Hidradenitis Suppurativa', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14375
,2024, 'Quality-of-life evaluation in hidradenitis suppurativa in Australia: Validation and outcomes of the HiSQOL questionnaire', Australasian Journal of Dermatology, http://dx.doi.org/10.1111/ajd.14370
,2024, 'Standardized Protocols for Clinical and Histopathological Characterization of Hidradenitis Suppurativa Tissue Specimens', Journal of Investigative Dermatology, http://dx.doi.org/10.1016/j.jid.2024.02.041
,2024, 'Systematic review and meta-analysis of non-SCORTEN predictors of mortality in Stevens-Johnson syndrome and toxic epidermal necrolysis', International Journal of Dermatology, http://dx.doi.org/10.1111/ijd.17529
,2024, '276 Full Spectrum Town Hall Meetings - Advancing Clinician-Patient-Researcher Engagement for Hidradenitis Suppurativa (HS)', Journal of Clinical and Translational Science, 8, pp. 84 - 84, http://dx.doi.org/10.1017/cts.2024.252
,2024, '52676 Safety and efficacy over one year of spesolimab treatment in patients with hidradenitis suppurativa (HS): Interim analysis of an open-label extension (OLE) study', Journal of the American Academy of Dermatology, 91, pp. AB83 - AB83, http://dx.doi.org/10.1016/j.jaad.2024.07.337
,2024, '52756 Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II', Journal of the American Academy of Dermatology, 91, pp. AB144 - AB144, http://dx.doi.org/10.1016/j.jaad.2024.07.575
,2024, 'Economic evaluation of HLA-B*15:02 genotyping in Asian Australian epilepsy patients', Clinical Medicine, 24, pp. 100131 - 100131, http://dx.doi.org/10.1016/j.clinme.2024.100131
,2024, 'Impact du bimékizumab sur le nombre de lésions par région anatomique dans l’hidradénite suppurée modérée à sévère : résultats à la semaine 48 de BE HEARD I&II', Annales de Dermatologie et de Vénéréologie - FMC, 4, pp. A361 - A361, http://dx.doi.org/10.1016/j.fander.2024.09.427
,2024, 'Lichenoid drug reaction to technicium-99: a case report and review of the literature.', Int J Womens Dermatol, 10, pp. e179, http://dx.doi.org/10.1097/JW9.0000000000000179
,2023, 'Attenuated PBMC Cytokine Production in Hidradenitis Suppurativa May Be Indicative of Cellular Exhaustion, Providing Novel Biomarkers, and Future Therapeutic Potential', Journal of Investigative Dermatology, 143, pp. 2334 - 2337, http://dx.doi.org/10.1016/j.jid.2023.05.020
,2023, 'Resident cutaneous memory T cells: a clinical review of their role in chronic inflammatory dermatoses and potential as therapeutic targets', British Journal of Dermatology, 189, pp. 656 - 663, http://dx.doi.org/10.1093/bjd/ljad303
,2023, 'Human dermal fibroblast subpopulations and epithelial mesenchymal transition signals in hidradenitis suppurativa tunnels are normalized by spleen tyrosine kinase antagonism in vivo', PLoS ONE, 18, pp. e0282763, http://dx.doi.org/10.1371/journal.pone.0282763
,2023, 'A proof-of-concept open-label clinical trial of spleen tyrosine kinase antagonism using fostamatinib in moderate-to-severe hidradenitis suppurativa', Journal of the American Academy of Dermatology, 89, pp. 694 - 702, http://dx.doi.org/10.1016/j.jaad.2023.05.076
,2023, 'Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis', Melanoma Research, 33, pp. 434 - 436, http://dx.doi.org/10.1097/CMR.0000000000000914
,2023, 'Knowledge, attitudes, and perceptions of hidradenitis suppurativa among young adults in Singapore', JAAD International, 12, pp. 72 - 80, http://dx.doi.org/10.1016/j.jdin.2023.03.010
,